Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Covering 2025–2034?
The market for alpha-1 antitrypsin deficiency augmentation therapy has experienced robust expansion over recent years. This market is projected to expand from $1.69 billion in 2024 to reach $1.8 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 6.2%. Factors contributing to its historical growth include better diagnosis, increased awareness campaigns, advancements in clinical research, and a growing aging population.
The market for alpha-1 antitrypsin deficiency augmentation therapy is anticipated to show significant expansion over the coming years. It is projected to achieve a value of ” $2.44 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. This expansion during the forecast period is primarily driven by advancements in telehealth and remote monitoring, precision medicine, and gene therapy developments. Notable trends expected within this timeframe involve the emergence of long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, and personalized dosing regimens.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Which Drivers Are Supporting Growth Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
The growing incidence of respiratory diseases is fueling the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are conditions that impact the lungs and the respiratory system, leading to breathing difficulties and diminished lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to address respiratory diseases by providing the deficient protein to individuals with alpha-1 antitrypsin deficiency. This therapy functions by restoring the balance of protease-antiprotease activity in the lungs, thereby protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Consequently, the increasing prevalence of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
What Are The Major Segment Categories Driving The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth?
The alpha-1 antitrypsin deficiency augmentation therapymarket covered in this report is segmented –
1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
2) By Route Of Administration: Oral; Injection; Inhalation
3) By End User: Hospitals; Specialty Clinics; Other End Users
What Are The Major Trends Driving The Growth Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Major companies active in the acute respiratory distress syndrome (ARDS) market are prioritizing the development of innovative therapies, such as drug development based on recombinant technology, to secure their market position. Recombinant DNA technology is utilized in the production of therapeutic pharmaceuticals, particularly for recombinant technology-based drug development. This methodology entails modifying the DNA of living organisms to synthesize specific proteins. For instance, in March 2022, Inhibrx Inc., a US-based biotechnology company, announced that INBRX-101 had obtained orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein that offers the potential for a once-monthly dosage. Its aim is to safely achieve and maintain AAT levels consistent with those found in healthy individuals.
Who Are The Prominent Global Companies Shaping The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp
Browse Through More Reports Similar to the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 2025, By The Business Research Company
Tnf Alpha Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report
5 Alpha Reductase Deficiency Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report
Alpha Glucosidase Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model